Business
Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST
Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n New York, NY, and Tel Aviv, ISRAEL, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that the management team of Todos Medical, including Mr. Gerald E. Commissiong, President and Chief Executive Officer, will host a conference call on Thursday, December 2nd at 4:30 p.m. EST to discuss the Company’s business progress in 2021 and provide a strategic outlook for the future. The call information is as follows: ·       Date:  December 2, 2021 ·       Time:  4:30 p.m. Eastern Standard Time ·       Direct Dial-in number: (669) 900-6833 ·       Meeting ID: 94945983568 ·       Passcode: 167897 This call is being webcast and can be accessed at https://audience.mysequire.com/webinar-view?webinar_id=6b97aec0-7ccb-4754-9a33-5c26d34d9597. The call will also be available for replay by accessing https://audience.mysequire.com/webinar-view?webinar_id=6b97aec0-7ccb-4754-9a33-5c26d34d9597. For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com. About Todos Medical Ltd. Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. In 2021, Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have re...